Hausstaubmilbe Dermatophagoides Farinae Hal Allergy (Dermatophagoides Farinae)

Hausstaubmilbe Dermatophagoides Farinae Hal Allergy is indicated for individuals with confirmed allergic sensitivity to the house dust mite Dermatophagoides farinae.

• Adjunct to allergen-specific immunotherapy programs aimed at reducing clinical symptoms.
• Use in skin testing to identify Dermatophagoides farinae sensitization.
• Support for desensitization protocols in patients with mild to moderate allergic rhinitis.
• Potential role in managing atopic dermatitis linked to dust‑mite allergy.
• Integration into comprehensive allergy management plans under specialist supervision.
• Facilitation of gradual exposure in controlled clinical settings to promote immunologic tolerance.

Local and systemic reactions may occur following cutaneous exposure to Dermatophagoides farinae extract; the frequency and severity vary among individuals.

Common

• Mild erythema or redness at the application site.
• Transient itching or pruritus.
• Localized swelling or edema.
• Brief sensation of warmth or tingling.
• Mild local pain or tenderness.
• Temporary dry skin or scaling.
• Slight increase in local temperature.
• Mild headache.
• Transient fatigue.
• Slight nausea.
• Occasional mild dizziness.
• Temporary localized flushing.
• Mild localized itching.
• Slight skin discoloration.

Serious

• Severe urticaria or widespread hives.
• Anaphylactic reaction requiring emergency medical attention.
• Significant respiratory distress or bronchospasm.
• Persistent angioedema affecting face or airway.
• Severe systemic hypotension.
• Cardiovascular collapse.

When using Hausstaubmilbe Dermatophagoides Farinae Hal Allergy, clinicians should evaluate patient history and monitor for adverse reactions to ensure safe application.

• Confirm documented Dermatophagoides farinae sensitization before initiation.
• Avoid use in individuals with a history of severe anaphylaxis to dust‑mite extracts.
• Conduct a supervised skin test prior to therapeutic dosing.
• Monitor patients for at least 30 minutes after application for early signs of systemic reaction.
• Pregnancy and lactation status should be assessed, as safety data are limited.
• Store the product according to manufacturer instructions, protecting it from light and extreme temperatures.
• Educate patients on recognizing and reporting any delayed or worsening symptoms.

Concurrent administration of other immunomodulatory agents may influence the safety profile of Dermatophagoides farinae extract; potential interactions should be reviewed before therapy.

Avoid

• Systemic antihistamines taken within 24 hours before skin testing, as they may suppress the test response.
• High‑dose systemic corticosteroids, which can diminish immunologic reactivity.
• Biologic agents such as omalizumab, which may modify IgE‑mediated responses.

Use with caution

• Topical corticosteroids applied near the test site, which may alter local skin response.
• Beta‑blockers, due to possible attenuation of emergency treatment for severe reactions.
• Immunotherapy agents targeting other allergens, requiring coordinated scheduling.
• ACE inhibitors, as they may affect blood pressure regulation during systemic reactions.
• Other immunomodulators that could alter immune response dynamics.